ABSTRACT OBJECTIVES This study sought to perform a systematic review and network meta-analysis to compare the relative safety and efficacy of contemporary DES and BVS.
everolimus-eluting BVS. In particular, the use of BVS has steeply increased with the expectations of its safety (11, 12) . However, data regarding BVS are still limited. Recent studies have shown that BVS is as efficacious as cobalt-chromium everolimus-eluting stents (CoCr-EES) in terms of repeat revascularization, but safety concerns have been raised as well (11) (12) (13) (14) .
In this study, we compared the safety of various contemporary DES including BVS in terms of the risk of stent thrombosis (ST) or device thrombosis. Due to the low incidence rates of ST, a very large sample size was required to detect differences in a single trial setting. A network meta-analysis has the advantage of providing comprehensive information by combining data from a complex network of multiple trials. For this purpose, we performed a systematic literature review of randomized controlled trials and updated a multiple-treatment network meta-analysis using a Bayesian framework. DESolve bioresorbable coronary scaffold (Elixir Medical, Sunnyvale, California), which have been approved by major regulatory authorities, were not included in this study, because they had limited comparisons with other devices (15, 16) . Exclusion criteria included studies comparing 2 stents with different stent designs within the same category described here, studies in which the specific type of DES was not predefined and the choice among avail- dual DES, and BVS had small sample sizes and limited comparisons with other devices.
METHODS
Characteristics of the included trials are summarized in Online Table 2 . There were 9 trials with a 3-arm design and 1 trial with a 4-arm design. Thirteen trials dedicatedly enrolled patients with diabetes mellitus, 25 enrolled those with ST-segment elevation MI, and 6 enrolled those with chronic total occlusion. An "allcomer design" was adopted in many of the recent large-scale clinical trials. Most trials comparing BVS had stringent inclusion and exclusion criteria. Figure 3 shows the distribution of the risk of bias of the included trials according to the Cochrane Collaboration's tool. 
estimates for early and late ST are shown in Online   Tables 3 and 4 , respectively.
Regarding definite ST, 107 studies involving 106,543 patients contributed to the analysis. As shown in Table 2 , BP-BES, SES, R-ZES, H-SES, CoCr-EES, and PtCr-EES were superior to BMS, and SES, CoCr-EES, and PtCr-EES were superior to PES. In addition, CoCr-EES was associated with a lower risk of ST than E-ZES, BP-BES, and SES. The rank of each stent was as follows: (BP-EES j PtCr-EES j CoCr-EES
OTHER SAFETY AND EFFICACY ENDPOINTS.
There were no statistical differences in any comparisons between study stents in terms of all-cause death or cardiac death (Online Tables 5 and 6 ). The results of MI within 1 year were similar to those of the primary endpoint (Online Table 7 ). SES, R-ZES, BP- Risk of bias of each included trial was assessed with the Cochrane Collaboration's tool. This risk-of-bias graph illustrates the proportion of studies with each of the judgments for each entry in the tool. Green represents "yes" (low risk of bias); yellow is "unclear"; red is "no" 
BMS ¼ bare-metal stent(s); BP-BES ¼ biodegradable polymer biolimus-eluting stent(s); BP-EES ¼ biodegradable polymer everolimus-eluting stent(s); BVS ¼ bioresorbable vascular scaffold(s); CoCr-EES ¼ cobalt-chromium everolimus-eluting stent(s); dual DES ¼ sirolimus-and probucol-eluting stent(s); E-ZES ¼ Endeavor zotarolimus-eluting stent(s); O-SES ¼ Orsiro sirolimus-eluting stent(s); PES ¼ paclitaxel-eluting stent(s); PtCr-EES ¼ platinum-chromium everolimus-eluting stent(s); R-ZES ¼ Resolute zotarolimus-eluting stent(s); SES ¼ sirolimus-eluting stent(s).

BES, E-ZES, PtCr-EES, CoCr-EES, and H-SES had a significantly lower risk of MI than BMS, whereas SES, BP-BES, E-ZES, PtCr-EES, CoCr-EES, and H-SES had a
significantly lower risk of MI than PES. PtCr-EES was superior to SES, and H-SES was superior to BVS.
All contemporary DES and BVS showed low risks of target vessel revascularization and target lesion revascularization (Online Tables 8 and 9 ). All DES were associated with reduced risk of repeat revascularization compared with BMS. PES and E-ZES were shown to be inferior to other contemporary devices.
In particular, BVS had a similar risk for repeat revascularization as the other DES such as SES, R-ZES, CoCr-EES, PtCr-EES, BP-BES, and H-SES. Table 11 ). The sensitivity analysis showed the same results as the main analysis except for the loss of statistical significance for the superiority of PtCr-EES to BVS.
The third sensitivity analysis was done comparing currently utilized stents only, namely CoCr-EES, PtCr- Table 12 ). There was a remarkable reduction in statistical power: 28 studies including 37,137 patients contributed to the analysis. Although the trends were similar to the main analysis, no comparisons were statistically significant, mainly due to the decrease in statistical power. Estimates from direct and indirect evidence were mostly consistent (Online Table 13 Preclinical and autopsy data showed that delayed Kang et al. 
EES, BP-EES, R-ZES, BP-BES, H-SES, dual DES, and BVS (Online
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